# Dexmedetomidine

Dexmedetomidine is a central α<sub>2</sub>-agonist (α<sub>2</sub>:α<sub>1</sub> activity 1600:1) used for its sedation and analgesic properties.

|Property|Action|
|--|--|
|**Class**|Imidazole derivative
|**Pharmaceutics**|D-stereoisomer of medetomidine (the L-stereoisomer is inactive)
|**Uses**|Sedation without respiratory depression
|**Presentation**|Clear colourless solution at 10µg.ml<sup>-1</sup>
|**Route of Administration**|IV only
|**Dosing**|0.2-0.7µg.kg<sup>-1</sup>.hr<sup>-1</sup>
|**Distribution**| 95% protein bound|
|**Metabolism**|Hepatic to inactive metabolites|
|**Elimination**|Renal of metabolites, t<sub>1/2</sub>β of 2 hours|
|**CVS**|Initial transient ↑ SVR and BP due to α<sub>1</sub> effects, followed by ↓ MAP, ↓ HR.<br><br> Rebound ↑ BP when abruptly ceased.
|**CNS**|Sedation, anxiolysis at low dose (anxiogenic at high dose), amnesia. ↓ MAC.<br><br> ↓ SNS outflow.

---
##References
1. Peck TE, Hill SA. Pharmacology for Anaesthesia and Intensive Care. 4th Ed. Cambridge University Press. 2014.  
2. Smith S, Scarth E, Sasada M. Drugs in Anaesthesia and Intensive Care. 4th Ed. Oxford University Press. 2011.
3. Petkov V. Essential Pharmacology For The ANZCA Primary Examination. Vesselin Petkov. 2012.